Research graph
References from Pharmacokinetic and Bioequivalence Evaluation of Febuxostat 40 mg Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions. Local targets link to admitted publications; unresolved targets remain external evidence.
Clinical significance of uric acid crystals in patients with uric acid nephropathy treated with febuxostat
2023 · External reference
Efficacy observation and influencing factors analysis of different doses of febuxostat in the treatment of gout with hyperuricemia
2023 · External reference
Efficacy of febuxostat tablets in the treatment of gout with hyperuricemia
2024 · External reference
Study on the efficacy and safety of febuxostat in patients with gout and hyperuricemia
2022 · External reference
Unresolved reference
2016 · External reference
Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007–2016
10.1002/art.40807 · 2019 · External reference
Guidelines for the diagnosis and treatment of hyperuricemia and gout in China (2019)
2020 · External reference
Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options
10.1186/s12916-017-0890-9 · 2017 · External reference
Bioequivalence of two febuxostat formulations in healthy Korean subjects under fasting and fed conditions
2020 · External reference
Pharmacokinetics and bioequivalence of two febuxostat 40 mg tablet formulations in healthy Chinese male volunteers
2016 · External reference
Effect of food on the pharmacokinetics of febuxostat in healthy Chinese subjects
2023 · External reference
Research progress on matrix effect in determination of human plasma drug concentration by LC‐MS/MS
2015 · External reference
